Johnson & Johnson Raises 2026 Guidance as Profit Falls to $210 Million

Johnson & Johnson reported third-quarter sales of $25.399 billion on Oct. 13, up 5.9% from $23.993 billion a year earlier, while net earnings fell sharply after a one-time special charge. Net earnings were $210 million, or 9 cents per diluted share, compared with $5.152 billion, or $2.12 per share, in the same quarter a year earlier. The company said the $0.09 quarterly EPS figure reflected a one-time special charge related to a proposed talc-litigation resolution, the Firefly Bio acquisition and a Sail Biomedicines collaboration. Innovative Medicine sales increased 7.7% to $16.757 billion. MedTech sales rose 2.5% to $8.642 billion.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.